Ginkgo Biloba

Ginkgo biloba sits in an unusual position in the supplement landscape. It has been more rigorously studied than almost any other botanical, it has a plausible mechanism, and it carries regulatory recognition in several European countries for use in dementia and cognitive impairment. Yet for the question most consumers are actually asking — can it protect my brain or prevent decline — two large, well-powered, long-term randomised trials came back null. This entry works through what the evidence does and does not support.

What it is

Ginkgo biloba is one of the oldest living tree species, with a history of medicinal use in traditional Chinese medicine spanning centuries. The standardised extract derived from its leaves is among the most extensively studied botanical preparations in clinical medicine. Most of the clinical trial evidence concerns a specific proprietary extract designated EGb 761, standardised to contain 24 percent flavone glycosides and 6 percent terpene lactones, with ginkgolic acid content below 5 parts per million. The flavonoids are thought to contribute antioxidant activity, while the terpene lactones — particularly ginkgolides and bilobalide — are considered the most pharmacologically active components, with proposed effects on platelet activating factor, cerebral blood flow, and neuronal protection.

Proposed mechanisms include inhibition of platelet activating factor, free radical scavenging, modulation of nitric oxide signalling, and effects on cholinergic and serotonergic neurotransmitter systems. These proposals are supported by in vitro and animal work, but they have not translated reliably into meaningful clinical outcomes, and mechanistic plausibility should not be treated as evidence of benefit.

The quality of commercial ginkgo products varies considerably. Many products on the market are not standardised to the same specification as EGb 761, and ginkgolic acid content is not always disclosed or controlled. Findings from trials using EGb 761 should not be assumed to apply to unstandardised products.

What the evidence shows

The most credible evidence for ginkgo concerns symptomatic management in adults with mild dementia. Several randomised controlled trials using EGb 761 at 240 mg daily for 22 to 24 weeks have demonstrated statistically significant improvements in cognitive performance, activities of daily living, and neuropsychiatric symptoms compared with placebo in this population. The evidence is more consistent in mild dementia than in mild cognitive impairment, where results across trials are more variable. Most positive trials are industry-sponsored and short-term, and the extent to which these effects translate into sustained or clinically meaningful improvements remains uncertain. The observed improvements are small in magnitude and may not translate into meaningful changes in independence, caregiver burden, or long-term disease trajectory. Compared with established pharmacological treatments for dementia such as cholinesterase inhibitors and memantine, the magnitude of effect from ginkgo appears smaller, and it is not considered a first-line therapy in most clinical guidelines.

For the question of whether ginkgo prevents dementia or cognitive decline in healthy older adults, the evidence is clearly and strongly negative. The GEM trial enrolled 3,069 adults aged 75 and over and followed them for a median of 6.1 years; ginkgo did not reduce dementia incidence or slow cognitive decline. The French GuidAge trial, following over 2,800 adults for five years, found no reduction in Alzheimer's disease incidence. Together these trials provide strong evidence that ginkgo does not prevent dementia.

For tinnitus, a Cochrane review of four trials found no evidence of benefit. For intermittent claudication, some earlier trials reported modest improvements in pain-free walking distance, but these effects are small, inconsistent, and not clinically competitive with supervised exercise therapy.

Five questions

Does low status cause harm? Ginkgo is not an endogenous compound and there is no defined deficiency state. The concept of low ginkgo status is not meaningful in nutritional or clinical terms.

Does supplementation prevent disease? No. The two largest and best-designed prevention trials found no reduction in dementia incidence over periods of five to six years. This is one of the clearest null results in the cognitive supplement literature and should be weighted heavily against marketing claims positioning ginkgo as a brain-protective supplement for general use.

Does it affect biomarkers? Ginkgo extract has demonstrated effects on platelet aggregation, cerebral blood flow, and markers of oxidative stress in some studies. These are surrogate findings and do not reliably predict clinical benefit, as the prevention trial results demonstrate.

Does it help clinical populations? There is a signal supporting symptomatic benefit in adults with mild dementia using standardised EGb 761 at 240 mg daily for at least 22 weeks. The evidence is weaker and less consistent in the broader MCI population. The magnitude of benefit is modest, most trials are industry-sponsored, and ginkgo is not a substitute for established dementia therapies.

Does it benefit healthy individuals? Evidence does not support cognitive benefit in healthy adults. Meta-analyses in cognitively intact individuals have not found consistent improvement, and prevention trials found no reduction in decline rates. Ginkgo is not evidenced as a general cognitive enhancer.

Individual variation

The clearest population for whom evidence exists is older adults, typically over 60, with diagnosed mild dementia. Positive trial results are most concentrated in this group. Evidence in mild cognitive impairment is less consistent. There is no meaningful evidence base in younger or middle-aged healthy adults, and extrapolating findings from dementia populations to healthy individuals is not supported.

Some observational and retrospective data from German clinical databases suggest an association between ginkgo prescriptions and slower progression of dementia severity, but these are subject to confounding and cannot establish causation. They are directionally consistent with RCT evidence in symptomatic populations but do not extend the evidence base to prevention or to broader populations.

There are no clinically meaningful data on differential response by sex, genetic variation, or baseline biomarker status. Women in the reproductive years have essentially no trial evidence relevant to cognitive outcomes from ginkgo supplementation, and the antiplatelet effects are a relevant consideration in the context of pregnancy.

Testing and status assessment

There are no blood or biomarker tests relevant to assessing whether ginkgo supplementation is likely to be beneficial for a given individual. There is no deficiency state to identify. The decision to trial ginkgo, where appropriate, is based on clinical presentation and population-level evidence rather than any individual biological measurement.

Safety

Ginkgo's most clinically relevant safety concern is its antiplatelet activity. The extract inhibits platelet activating factor and may reduce platelet aggregation, increasing the risk of bleeding. This risk is most significant when ginkgo is combined with anticoagulants such as warfarin or heparin, or with antiplatelet drugs such as aspirin or clopidogrel, where additive effects on bleeding have been reported. Ginkgo should be stopped at least one to two weeks before elective surgery or any procedure with significant bleeding risk.

The most common adverse effects are gastrointestinal, including nausea, stomach upset, and diarrhoea, particularly at higher doses. Headache and dizziness are occasionally reported. Allergic reactions can occur, particularly in individuals with sensitivity to plants in the Anacardiaceae family such as poison ivy or cashews, which share structural similarities with some ginkgo compounds.

Ginkgolic acid, present in the raw ginkgo plant, is potentially toxic and allergenic. Standardised EGb 761 is produced with ginkgolic acid content below 5 parts per million. Products not standardised to this specification may contain higher levels and should be avoided. The seeds and raw plant are not safe for consumption.

Case reports have associated ginkgo with spontaneous bleeding events including subdural haematoma, though causation is difficult to establish given confounding medication use in many reported cases. The absolute risk in otherwise healthy individuals not taking interacting medications is likely low, but the potential for serious bleeding warrants consideration in anyone on anticoagulant or antiplatelet therapy.

Use during pregnancy is not recommended given the antiplatelet effects and absence of safety data.

What can reasonably be concluded

Ginkgo biloba at 240 mg daily of standardised EGb 761 has a modest and partially consistent evidence base for symptomatic benefit in adults with mild dementia. The evidence is weaker in mild cognitive impairment and absent in healthy adults. Most positive trials are industry-sponsored, short-term, and rely on surrogate cognitive scales rather than outcomes that directly reflect independence or quality of life. The magnitude of effect is smaller than that seen with established pharmacological dementia treatments, and ginkgo is not considered a first-line therapy in clinical guidelines.

For prevention of cognitive decline or dementia, the evidence is clearly negative. Two large, long-term trials found no effect on dementia incidence or rate of cognitive decline. There is no evidence that ginkgo improves long-term independence or alters disease trajectory. For tinnitus, evidence is null. For peripheral circulation, effects are modest, inconsistent, and not clinically competitive with exercise therapy. Ginkgo is not evidenced as a general cognitive enhancer, and the gap between its marketing and its evidence base is large.

The bleeding risk is real and clinically relevant for those on anticoagulant or antiplatelet therapy. Only standardised EGb 761 at adequate dose and duration reflects the trial evidence; the majority of over-the-counter products are not equivalent.

Where evidence is limited or outcomes are uncertain, conclusions should be treated as provisional and subject to revision as the evidence base develops.